$RARX News
Last published 1mo ago
- 1mo agoRARXUCB Capital Market Update Call - RA PHARMACEUTICALS INCEarnings Call TranscriptsHello, everyone, and welcome to UCB's EADV Capital Markets Call for Institutional Investors and Analysts. My name is Yvonne Knowlton, and I lead the Investor Relations team here at UCB. Today's presentation is available
- 6y agoRARXRa Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare DiseasesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13th Annual Rare Disease Day®, an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face.
- 6y agoRARXRa Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments.
- 6y agoRARXRa Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA NeurologyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA Neurology publication can be accessed here.
- 6y agoSYBXRARXCerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of DirectorsBusiness WireBOSTON--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the appointment of Aoife Brennan, M.B., B.Ch., to its board of directors effective January 1, 2020.
- 6y agoRARXRa Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNMBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM).
- 6y agoLPTPRTORARXCARTMoore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Trust BancShares (CART), and Highlands Bankshares (HLND) Investors to Contact FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors...
- 7y agoRARXRa Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the third quarter ended September 30, 2019, and provided an update on recent corporate and clinical developments.
- 7y agoRARXUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare DiseasesPR NewswireRegulated Information – Inside Information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger...
- 7y agoRARXUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare DiseasesBusiness WireBRUSSELS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive US$ 48 in cash for each Ra Pharma share at closing. The Boards of Directors of bot ...
- 7y agoRARXRa Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMGBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG).
- 7y agoRARXRa Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass GeneralBusiness WireBOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS), led by the Sean M. Healey & AMG Center for ALS at Mass General. The Healey Center has agreed to provide funding for the execution of the platform ...
- 7y agoRARXRa Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia GravisBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis (gMG) ...
- 7y agoRARXRa Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with MerckBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that it has earned a clinical development milestone under its collaboration agreement with Merck, known as MSD outside the U.S. and Canada. The milestone is associated with the dosing of the first patient in a Phase 1 clinical trial evaluating an investigational orally-available macrocyclic peptide for a non- ...
- 7y agoRARXRa Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the second quarter ended June 30, 2019, and provided an update on recent corporate and clinical developments.
- 7y agoRARXRa Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The gross proceeds from the offerin ...
- 7y agoRARXRa Pharmaceuticals Announces Pricing of Public Offering of Common StockBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, at a public offering price of $32.50 per share. Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. The gross proceeds from the offerin ...
- 7y agoRARXRa Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock. There can be no ass ...
- 7y agoRARXRa Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of ZilucoplanPR NewswireRa Pharmaceuticals, Inc. (Nasdaq: RARX) and Camurus AB (Nasdaq STO: CAMX) today announced an exclusive worldwide license agreement for the use of...